Original Publications from Dr. Glaser
Dr. Glaser has devoted her life to researching, treating, and preventing breast cancer. Prior to performing pellet insertions, Dr. Glaser was a breast cancer surgeon. She is currently researching subcutaneous testosterone therapy and breast cancer. She has evaluated and treated over 1500 breast cancer patients. At the Millennium Wellness Center, she currently treats both men and women with testosterone pellet therapy.
Dr. Glaser believes in open access to her research. Below is a collection of her articles and presentations from various peer-reviewed journals and conferences. This information is provided as educational material only and should not be used for diagnosis or treatment.
Additional information is hosted on trocarkit.com. Dr. Glaser’s research can also be found on ResearchGate.
Peer Reviewed Publications
| Title | Year | Full Text | Publication |
|---|---|---|---|
| Intracrinology and Testosterone Pellet Therapy: An Enzyme-Aware, Symptom-Driven Approach to Hormone Optimization in Aging | 2026 | Full Text | Cureus |
| Incidence of Invasive Breast Cancer in Women Treated with Testosterone Implants: Dayton Prospective Cohort Study, 15-Year Update | 2025 | Full Text | Adv Prev Med Health Care 8: 1070 |
| Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors | 2021 | Journal of the Endocrine Society | |
| Testosterone implant therapy in women with and without breast cancer: Rationale, Experience, Evidence | 2021 | Full Text | Androgens: Clinical Research and Therapeutics |
| Testosterone/Aromatase Inhibitor Therapy in Advanced Breast Cancer: A case series | 2021 | Androgen Society 3rd annual meeting March 13, 2021 | |
| A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102 | 2020 | Full Text | Supportive Care in Cancer |
| Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study | 2019 | Full Text | BMC Cancer |
| Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. Supplement 1. Statistical Methods | 2019 | Full Text | BMC Cancer |
| Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy | 2019 | Full Text | Int J Pharm Compd |
| Reduced incidence of breast cancer with testosterone implant therapy: a 10-year cohort study | 2018 | Full Text | 2018 San Antonio Breast Cancer Symposium. 2018, December: P6-13-02 |
| A randomized, double-blind, placebo-controlled trial of testosterone (T) for aromatase inhibitor-induced arthralgias (AIA) in postmenopausal women: Alliance A221102 | 2018 | Full Text | 2018 San Antonio Breast Cancer Symposium. 2018, December: P4-16-01 |
| Breast cancer treatment in women over the age of 80: A tailored approach | 2017 | Full Text | Maturitas |
| Testosterone, anastrozole and venous thrombosis | 2017 | Full Text | Maturitas |
| Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: 9-year* interim analysis | 2017 | Full Text | Maturitas |
| Oral presentation and abstract. Critical role of testosterone in both sexes | 2017 | Full Text | Maturitas |
| Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications | Full Text | Menopause | |
| Effect of testosterone therapy on the female voice | 2016 | Full Text | Climacteric |
| Testosterone and breast cancer prevention | 2015 | Full Text | Maturitas |
| Reduced incidence of breast cancer in women adherent to testosterone or testosterone-anastrozole hormone therapy: updated interim analysis | 2015 | Full Text | Maturitas |
| Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer | 2014 | Full Text | Menopause (New York, NY) |
| Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors | 2014 Sep 10 | Full Text | J Clin Oncol |
| THE EFFECTS OF SUBCUTANEOUS TESTOSTERONE IMPLANTATION ON THE FEMALE VOICE | 2013 | Full Text | 10th International Conference Advances in Quantitative Laryngology; 2013; |
| Testosterone therapy in women: Myths and misconceptions | 2013 | Full Text | Maturitas |
| Testosterone implants in women: pharmacological dosing for a physiologic effect | 2013 | Full Text | Maturitas |
| Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study | 2013 | Full Text | Maturitas |
| Testosterone pellet implants and migraine headaches: a pilot study | 2012 | Full Text | Maturitas |
| Subgroups of patients treated with an aromatase inhibitor (anastrozole) delivered subcutaneously in combination with testosterone | 2012 | 9th European Congress on Menopause and Andropause. Athens, GR 424; 2012; | |
| Improvement in scalp hair growth in androgen deficient women treated with testosterone: a questionnaire study | 2012 | Full Text | British Journal of Dermatology |
| 58 BENEFICIAL EFFECTS OF SUBCUTANEOUS TESTOSTERONE THERAPY ON LIPID PROFILES IN WOMEN | 2012 | Full Text | Maturitas |
| 14 SUBGROUPS OF PATIENTS TREATED WITH AN AROMATASE INHIBITOR (ANASTROZOLE) DELIVERED SUBCUTANEOUSLY IN COMBINATION WITH TESTOSTERONE | 2012 | Full Text | Maturitas |
| Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS) | 2011 | Full Text | Maturitas |
| Subcutaneous testosterone-anastrozole implant therapy in breast cancer survivors | 2010 | Full Text | |
| Low salivary testosterone levels in patients with breast cancer | 2010 | Full Text | BMC cancer |
| The protective role of androgens: salivary hormone levels in newly diagnosed breast cancer patients | 2009 | 26th Annual Miami Breast Cancer Conference: March 4-7, 2009; Miami, FL; | |
| Safety of maternal testosterone therapy during breast feeding | 2009 | Full Text | International journal of pharmaceutical compounding |
| Efficacy of testosterone therapy delivered by pellet implant | 2009 | Full Text | Maturitas |
| Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina | 2008 | Full Text | Gynecologic and obstetric investigation |
| The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy | 2002 | Full Text | Annals of surgical oncology |
| Accuracy of sentinel lymph node biopsy for patients with T-2 and T-3 Breast cancer (vol 67, pg 522, 2001) | 2002 | Full Text | AMERICAN SURGEON |
| Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multi-institutional study | 2001 | Full Text | Annals of surgery |
| Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques | 2001 | Full Text | Annals of surgery |
| Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used | 2000 | Full Text | Journal of Clinical Oncology |
| Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes | 2000 | Full Text | Annals of surgery |
| Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study | 2000 | Full Text | Surgery |
| ORIGINAL REPORTS-Breast Cancer-Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used | 2000 | Journal of Clinical Oncology | |
| Sentinel lymph node biopsy for breast cancer: A suitable alternative to routine axillary dissection in multiinstitutional practice when optimal technique is used | 2000 | Full Text | J Clin Onco |
| Correlation of FDG PET and sentinel lymph node biopsy in patients with breast cancer | 2000 | Full Text | JOURNAL OF NUCLEAR MEDICINE |
| FDG PET IN BREAST-CANCER | 1994 | Journal of Nuclear Medicine | |
| Arteriovenous fistulas after cardiac catheterization | 1989 | Full Text | Archives of Surgery |
| Chronic esophageal ulcers in an AIDS patient | 1986 | Full Text | Gastrointestinal endoscopy |
Why Testosterone Pellet Therapy?
Subcutaneous testosterone pellet therapy offers a superior alternative to traditional hormone replacement therapies (HRT), injections, and gels.
- Stable & Consistent Hormone Levels – Pellets provide a steady release of testosterone, avoiding the fluctuations seen with other methods.
- Long-Lasting Results – One treatment lasts 3 to 6 months, reducing patient compliance issues.
- More Effective Symptom Relief – Studies show testosterone alone can alleviate fatigue, brain fog, weight gain, and mood instability more effectively than estrogen-based HRT.
- Clinically Proven Benefits – Research has shown that higher testosterone levels correlate with improved cognitive function, metabolic health, and quality of life.
What You’ll Get in a Consultation:
- Stable & Consistent Hormone Levels – Pellets provide a steady release of testosterone, avoiding the fluctuations seen with other methods.
- Long-Lasting Results – One treatment lasts 3 to 6 months, reducing patient compliance issues.
- More Effective Symptom Relief – Studies show testosterone alone can alleviate fatigue, brain fog, weight gain, and mood instability more effectively than estrogen-based HRT.
- Clinically Proven Benefits – Research has shown that higher testosterone levels correlate with improved cognitive function, metabolic health, and quality of life.
By incorporating testosterone pellet therapy into your practice, you can provide your patients with a research-backed, life-changing treatment option.
How to Get Started
We make it easy for healthcare professionals to integrate testosterone therapy into their practice.
- Step 1: Schedule a Consultation – Speak with our team to discuss your goals and how testosterone therapy fits into your practice.
- Step 2: Enroll in Our Training Program – Gain access to exclusive educational materials, case studies, and dosing protocols
- Step 3: Implement Treatment Protocols – Begin offering testosterone pellet therapy using proven methodologies supported by our team.
- Step 4: Ongoing Support & Collaboration – Stay connected with Millennium Wellness Center for continued education, updated research, and expert consultation services.
Testimonials from Healthcare Providers
FAQ's
Why pellets?
In studies, when compared to conventional hormone replacement therapy, pellets have been shown to be superior for relief of menopausal symptoms, maintenance of bone density, restoration of sleep patterns, and improvement in sex drive, libido, sexual response and performance.
Testosterone delivered by a pellet implant, has been used to treat migraine and menstrual headaches. It also helps with vaginal dryness, incontinence, urinary urgency and frequency. In both men and women, testosterone has been shown to increase energy, relieve depression, increase sense of well being, relieve anxiety and improve memory and concentration. Testosterone, delivered by pellet implant, increases lean body mass (muscle strength, bone density) and decreases fat mass. Men and women need adequate levels of testosterone for optimal mental and physical health and for the prevention of chronic illnesses like Alzheimer's and Parkinson's disease, which are associated with low testosterone levels.
Even patients who have failed other types of hormone therapy have a very high success rate with pellets. There is no other ‘method of hormone delivery' that is as convenient for the patient as the implants. Implants have been used in both men and women since the late 1930's. There is significant data that supports the use of testosterone implants in both men and women.
What are signs and symptoms of androgen (testosterone) deficiency in men and women?
Sarcopenia, muscle loss, aches, decreased strength
Changes in cognition, mental focus, and memory
Insomnia, sleep disturbance
Urinary incontinence, vaginal dryness, prostate issues
Diminished sense of well-being
Dysphoric mood (sadness, depression, anxiety, irritability)
Persistent, unexplained fatigue
Sexual – decreased performance, libido, receptivity and pleasure
Vasomotor instability (hot flashes), heart discomfort (A-Fib)
How and where are pellets inserted?
Are there any side effects or complications from the insertion of the pellets?
Testosterone may cause a slight increase in facial hair in some women. Testosterone stimulates the bone marrow and increases the production of red blood cells. A low testosterone level in older men is a cause of anemia. Testosterone, delivered by implants or other methods, can cause an elevation in the red blood cells. If the hemoglobin and hematocrit (blood count) get too high, a unit of blood may be donated.
After the insertion of the implants, vigorous physical activity is avoided for 48 hours in women and up to 5 to 7 days in men. Early physical activity is a cause of ‘extrusion', which is a pellet working it's way out. Antibiotics may be prescribed if a patient is diabetic or has had a joint replaced. However, this is a ‘clean procedure' and antibiotics may not be needed.
Why haven't I heard about Pellets?
Do men need hormone therapy?
What if my primary care physician or my gynecologist says that there is ‘no data' to support the use of testosterone implants?
Do testosterone implants have the same danger of breast cancer as other forms of hormone replacement therapy?
In contrast to testosterone, Estradiol, whether delivered by pellet implant*, applied topically to the skin or taken orally has been shown to increase the risk of breast cancer. This is not surprising, as continuous Estradiol, a strong estrogen, has been shown to stimulate breast tissue.
*Million Women’s Study
Can breast cancer patients be treated with testosterone pellets? Is it safe?
Are there other hormones besides testosterone that have not been shown to increase the risk of breast cancer?
Estriol is a bio-identical estrogen widely used in Europe that does not bind strongly to estrogen receptor and does not stimulate breast tissue. We have shown that pre-menopausal women diagnosed with breast cancer had lower levels of estriol than controls, i.e. women without breast cancer. Numerous studies have shown that vaginal estriol does not increase the risk of breast cancer (RR 0.7). It has safely been used in breast cancer survivors. ‘High dose’ (>25 mcg) vaginal estrogens like Estrace® (estradiol) and vaginal Premarin® provide systemic levels of strong estrogens that may stimulate breast tissue. However, Vagifem®, which delivers smaller doses of estrogen (10 mcg) is considered ‘local’ therapy and may be a safe option for vaginal hormone therapy in breast cancer patients. If you are a breast cancer survivor, it is important that your physician understands this concept.
Why isn’t estrogen therapy or Estradiol pellet therapy recommended?
Almost all symptoms, including hot flashes, are relieved with testosterone pellets alone. A study by Sherwin in 1985 looked at testosterone, testosterone with estradiol, estradiol alone and placebo. The group of women who responded best (somatic, psychological and total score)…testosterone alone! The groups that did the worst…estrogen alone and placebo. Higher levels of testosterone were associated with a better response. These results are expected. Testosterone is the major ‘substrate’ for estrogen production in the brain, bones, vascular system, breast and adipose tissue. Some physicians do not understand this and may insist that estrogen therapy is needed.
Excess estrogen can cause anxiety, weight gain, belly fat, tender breasts, emotional lability, symptoms of PMS, and mood swings. Long-term exposure to stronger estrogens like estradiol and Premarin can increase the risk of breast cancer. In addition, there is exposure to many estrogen-like chemicals.
Some women (and men) ‘aromatize’ or convert too much testosterone to estradiol, which can interfere with the beneficial effects of testosterone. An ‘aromatase inhibitor’ (i.e. anastrozole) may be prescribed to prevent this. Patients, including breast cancer survivors and men with elevated estrogens, may be treated with the combination testosterone-anastrozole implants.
Will hormone therapy with testosterone pellets help with hair loss?
Do testosterone pellets cause voice changes in women?
Do testosterone pellets increase the risk of blood clots?
How long until a patient feels better after pellets are inserted?
How long do pellets last?
Do patients need progesterone when they use the pellets?
However, if estradiol, or other estrogen therapy is prescribed, progestins are also needed. The main indication for the use of synthetic progestins, like Provera® or progesterone, is to prevent the proliferation (stimulation) of the uterine lining caused by estrogen. Progestin therapy is NOT required if estrogen therapy is not prescribed. However, there may be other health benefits from the hormone, progesterone. It may help with anxiety or insomnia. Interestingly, progesterone implants have been used since the 1940’s.
How are hormones monitored during therapy?
In men, follow up levels, including a PSA, blood count and estradiol, may be obtained prior to subsequent testosterone implantation. Men must notify their primary care physician and obtain a digital rectal exam each year. Women are advised to continue their monthly self-breast exam and obtain a mammogram and/or pap smear as advised by their gynecologist or primary care physician.
How much does this cost?
When compared to the cost of drugs to treat the individual symptoms of hormone decline, pellets are very cost effective.
Will insurance cover the procedure?
Patients are able to ‘appeal' a denied claim.
Is there a role for testosterone implants (pellets) in a pre-menopausal female?
Can a patient be allergic to the implants?
Join the Future of Hormone Therapy
Ready to enhance your expertise and patient outcomes? Partner with us to integrate testosterone pellet therapy and bring research-based hormone therapy to more patients.